top of page

Free Biopharma Daily Stock Updates - 03/04/22

$XBI $83.90 | -3.17%

 

Pipeline Updates

$CHRS +2.5% Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell. source


$EQ -0.6% Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease. source


$TGTX -6.2% TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting. source


$OCGN -23.1% Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request. source


$EVFM -10.2% Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women. source


$IONS -2.8% Key learnings from GENERATION HD1 study of tominersen highlighted at CHDI 2022. source


Business Updates

$NTLA -8.4% Intellia Therapeutics’ Statement on Recent U.S. Patent and Trademark Office Decision Relating to CRISPR/Cas9 Genome Editing Technology in Eukaryotic Cells. source


$CASI -4.0% CASI Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China. source


$EYEN -2.3% EYENOVIA STRENGTHENS BALANCE SHEET WITH A $15 MILLION INSTITUTIONAL CAPITAL INVESTMENT FROM ARMISTICE CAPITAL MASTER FUND LTD. source



 

Posted by DV/FS

0 comments
bottom of page